ArticleFrontiers in medicine2025
Machine learning insights into early mortality risks for small cell lung cancer patients post-chemotherapy.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comparative Analysis of Machine Learning Algorithms for Prognostic Prediction in Pulmonary Large Cell Carcinoma.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Small cell lung cancer (SCLC) is a highly aggressive form of lung cancer, and chemotherapy remains a cornerstone of its management. However, the treatment is associated with significant risks, including heightened toxicity and early mortality. This study aimed to quantify the 90-day mortality rate post-chemotherapy in SCLC patients, identify associated features, and develop a predictive machine learning model. Methods: This study utilized data from the Surveillance, Epidemiology, and End Results (SEER) database (2000-2018) to identify prognostic features influencing early mortality in SCLC patients. Prognostic features were selected through univariate logistic regression and Lasso analyses. Predictive modeling was performed using advanced machine learning algorithms, including XGBoost, Multilayer Perceptron, K-Nearest Neighbor, and Random Forest. Additionally, traditional models, such as logistic regression and AJCC staging, were employed for comparison. Model performance was evaluated using key metrics, including the Area Under the Receiver Operating Characteristic Curve (AUC), calibration plots, the Kolmogorov-Smirnov (KS) statistic, and Decision Curve Analysis (DCA). Results: Analysis of 12,500 eligible patients revealed 10 clinical features significantly impacting outcomes. The XGBoost model demonstrated superior discriminatory capability, achieving AUC scores of 0.95 in the training set and 0.78 in the validation set. It outperformed comparative models across all datasets, as evidenced by its AUC, KS score, calibration, and DCA results. Additionally, the model was integrated into a web-based platform to improve accessibility. Conclusion: This study introduces a machine learning model alongside a web-based support system as critical resources for healthcare professionals, facilitating personalized clinical decision-making and enhancing treatment strategies for SCLC patients post-chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.